GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, announced its financial results for the year ended December 31, 2025, and provided an update on its pipeline, with a focus on its lead candidate GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. The company plans to initiate a pivotal Phase 3 immuno-bridging study in the second half of 2026, following regulatory alignment with the European Medicines Agency (EMA) and completion of cGMP manufacturing and fill-finish of clinical-grade GEO-MVA.
GEO-MVA is being developed on an expedited regulatory pathway to address a documented global supply constraint in orthopoxvirus vaccines, supporting public health preparedness and biosecurity needs, including diversification of supply away from a single foreign manufacturer. The EMA's Scientific Advice supported a streamlined development pathway, allowing a single Phase 3 study without prior Phase 1 or 2 trials. GeoVax believes GEO-MVA is uniquely positioned amid recurring global mpox outbreaks, depleted government stockpiles, and policy-driven demand for diversified vaccine supply.
Beyond GEO-MVA, the company is advancing GEO-CM04S1, a COVID-19 vaccine candidate, through multiple Phase 2 trials targeting immunocompromised populations, with data readouts expected in 2026. In oncology, Gedeptin, a gene-directed enzyme prodrug therapy, completed a Phase 1/2 trial in advanced head and neck cancer, and GeoVax entered into an exclusive license agreement with Emory University to support combination with immune checkpoint inhibitors. A Phase 2 trial for first-line treatment is planned for 2027.
Financially, GeoVax reported a net loss of $21.5 million for 2025, compared to $25.0 million in 2024. Revenue from government contracts decreased to $2.5 million from $4.0 million, primarily due to the termination of the BARDA/RRPV Project NextGen award in April 2025. Research and development expenses fell to $18.1 million from $23.7 million, reflecting lower costs from the BARDA contract termination and reduced spending on GEO-CM04S1 and Gedeptin programs. General and administrative expenses increased to $6.0 million from $5.4 million, driven by higher personnel and investor relations costs. Cash and cash equivalents stood at $3.1 million as of December 31, 2025, down from $5.5 million at the end of 2024.
David Dodd, Chairman and CEO of GeoVax, stated, "During 2025, we made significant progress advancing GEO-MVA toward late-stage clinical development, supported by regulatory alignment with the EMA and key manufacturing milestones. We believe GEO-MVA represents a critically important opportunity to eliminate the current global supply constraint in orthopoxvirus vaccines, while supporting broader public health preparedness and biosecurity objectives." He added, "As we look ahead, our priority is executing key GEO-MVA clinical and regulatory milestones, strengthening strategic partnerships, while selectively advancing other programs."
The company's focus on GEO-MVA comes amid ongoing global mpox outbreaks and evolving viral strains, which have highlighted the need for diversified vaccine supply. GeoVax is actively engaging with international regulatory and governmental stakeholders to align GEO-MVA with public health preparedness frameworks. For more information, visit GeoVax's website.
